Denali Therapeutics Inc. (NASDAQ:DNLI) Expected to Earn FY2025 Earnings of ($2.86) Per Share

Denali Therapeutics Inc. (NASDAQ:DNLI) – Zacks Research lowered their FY2025 earnings estimates for Denali Therapeutics in a note issued to investors on Wednesday, June 19th. Zacks Research analyst A. Chakraborty now forecasts that the company will earn ($2.86) per share for the year, down from their prior estimate of ($2.83). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.78) per share. Zacks Research also issued estimates for Denali Therapeutics’ Q4 2025 earnings at ($0.72) EPS, Q1 2026 earnings at ($0.68) EPS and FY2026 earnings at ($2.76) EPS.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.01. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 11.46%. During the same quarter in the previous year, the business posted ($0.80) EPS.

Other analysts have also recently issued reports about the stock. Stifel Nicolaus lowered their price target on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a report on Wednesday, May 8th. UBS Group decreased their price objective on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, April 9th. Wedbush decreased their price objective on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, May 8th. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Denali Therapeutics in a research report on Wednesday, May 8th. Finally, The Goldman Sachs Group reduced their price target on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.22.

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $22.91 on Monday. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $30.79. The stock has a market capitalization of $3.27 billion, a P/E ratio of -23.86 and a beta of 1.37. The company’s 50-day simple moving average is $18.98 and its 200-day simple moving average is $19.19.

Institutional Trading of Denali Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC grew its position in Denali Therapeutics by 216.7% in the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after acquiring an additional 1,376 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Denali Therapeutics by 48.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after buying an additional 807 shares in the last quarter. Fisher Asset Management LLC acquired a new position in shares of Denali Therapeutics during the fourth quarter worth about $59,000. Assetmark Inc. grew its position in shares of Denali Therapeutics by 65.3% during the fourth quarter. Assetmark Inc. now owns 3,550 shares of the company’s stock worth $76,000 after buying an additional 1,402 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new position in shares of Denali Therapeutics during the first quarter worth about $88,000. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics stock in a transaction on Monday, April 15th. The shares were sold at an average price of $18.29, for a total transaction of $30,471.14. Following the sale, the director now owns 118,043 shares of the company’s stock, valued at approximately $2,159,006.47. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Jennifer E. Cook sold 1,458 shares of Denali Therapeutics stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $21.73, for a total transaction of $31,682.34. Following the transaction, the director now owns 20,038 shares in the company, valued at approximately $435,425.74. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 1,666 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $18.29, for a total transaction of $30,471.14. Following the completion of the sale, the director now owns 118,043 shares in the company, valued at $2,159,006.47. The disclosure for this sale can be found here. In the last quarter, insiders have sold 95,624 shares of company stock valued at $1,958,403. 7.90% of the stock is owned by company insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.